Indianarise Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.50 M
- Revenue Growth 138.33%
- Profit Growth 178.65%
- Ebitda 121.55%
- Net Worth 3.19%
- Total Assets 5.38%
About Indianarise Pharmaceuticals
Indianarise Pharmaceuticals Private Limited (IPPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 March 2014 and has a history of Ten years and 11 months. Its registered office is in Delhi, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.50 M.
Jeetendra Kumar, Shyam Narayan, Vijay Tiwari, and One other member serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24233DL2014PTC265686
- Company No.
265686
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Mar 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Indianarise Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jeetendra Kumar  | Director | 03-Mar-2014 | Current |
| Shyam Narayan | Director | 03-Mar-2014 | Current |
| Vijay Tiwari | Director | 03-Mar-2014 | Current |
| Rajendra Pandey | Director | 03-Mar-2014 | Current |
Financial Performance of Indianarise Pharmaceuticals.
Indianarise Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 138.33% increase. The company also saw a substantial improvement in profitability, with a 178.65% increase in profit. The company's net worth moved up by a moderate rise of 3.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Indianarise Pharmaceuticals?
In 2017, Indianarise Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Tantaa Pharmaceutical Private LimitedShyam Narayan is a mutual person
Charges (Loans)
₹0.50 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.05 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Jul 2016 | Others | ₹0.50 M | Open |
How Many Employees Work at Indianarise Pharmaceuticals?
Unlock and access historical data on people associated with Indianarise Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Indianarise Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Indianarise Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.